April 28, 2008 - CVRx introduced a new device for high blood pressure engineered to treat hypertension patients whose conditions are not controlled by drugs, and aims to reduce systolic blood pressure.
Rheos Hypertension (HT) Therapy, which is now in clinical trials, is an implantable device and uses the body's natural blood pressure sensor (the baroreflex) to reduce blood pressure. Early hypertension clinical trial results showed a 39 mmHg reduction in systolic blood pressure at one year of use.
The Rheos HT Therapy is designed to electrically activate the carotid baroreceptors. When the baroreceptors are activated, signals are sent through the neural pathways to the brain and interpreted as a rise in blood pressure. The brain works to counteract this perceived rise in blood pressure by sending signals to various parts of the body, including the blood vessels, heart and kidneys.
For more information: www.cvrx.com and www.bloodpressuretrial.com